Free tool
Rare disease stocks
We cover 5 companies grouped under the Rare disease theme. The median market value in the group is $381.21M. Across the group, the median move over the past trading day is −0.57%. Price change over the past year runs from −34.1% to +16.8% across the middle 80 percent of the group, with a median of −28.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| ABVX.PA | ABIVAX Société Anonyme | 98.10 EUR | −9.83% | −14.70% | +42.59% | Sep 21, 2026 |
| RZLT | Rezolute, Inc. | $5.01 | +1.42% | +131.41% | −28.43% | Sep 16, 2026 |
| CUV.AX | Clinuvel Pharmaceuticals Limited | 10.54 AUD | +7.44% | −17.07% | −21.84% | Aug 27, 2026 |
| 0AB6.L | Hyloris Pharmaceuticals SA | 4.46 EUR | −0.66% | −37.71% | −32.01% | Sep 24, 2026 |
| INM | InMed Pharmaceuticals Inc. | $1.44 | −12.20% | +28.57% | −35.43% | Sep 23, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.